According to recently leaked secret records (read the pdf below), Pfizer hired 1,800 additional full-time employees in the first half of 2021 to deal with “the large increase” in adverse reactions to its COVID vaccination.
- MAJOR PEER REVIEWED STUDY: Moderna Vaccine Increases Myocarditis Risk By 44 Times In Young Adults
- MUST READ: High Level International Bankers Simulate The Collapse Of Global Financial System
- BIG STORY: Wuhan Lab Isolated Monkeypox Strain In 2020
- EXPLOSIVE: Ukraine Biolabs Used Fever Carrying Mosquitoes To Spark Dengue Pandemic In Cuba
On December 11, 2020, the Pfizer-BioNTech COVID-19 Vaccine was made accessible under an Emergency Use Authorization (EUA). By February 2021, the company had seen so many warning signs, particularly in pregnant and breastfeeding mothers, that it needed to hire 600 people to analyse the information.
“Pfizer has also taken a multiple actions [sic] to help alleviate the large increase of adverse event reports. This includes significant technology enhancements, and process and workflow solutions, as well as increasing the number of data entry and case processing colleagues,” the confidential report stated. “To date, Pfizer has onboarded approximately 600 additional full-time employees (FTEs). More are joining each month with an expected total of more than 1,800 additional resources by the end of June 2021.”
On April 1, the FDA disclosed 10,000 pages of Pfizer-COVID-19 BioNTech’s vaccine evaluation materials, in response to a court order issued in January requiring the company to speed up the process of making the information public.
U.S. District Judge Mark Pittman of the Northern District of Texas issued an order directing the FDA to produce around 12,000 records immediately, followed by 55,000 pages per month until all documents — totalling more than 300,000 pages — are revealed.
Subscribe to GreatGameIndia
Last month, the FDA revealed a slew of documents revealing that the company was aware that the mRNA injections could cause over 1,000 different types of side effects.
The most recent findings were made in a document titled “Cumulative analysis of post-authorization adverse event reports” for the Pfizer-BioNTech vaccine, which covered adverse events reported from February 28, 2021 to February 28, 2022.
The documents were first made public in November 2021, but much of the information was censored, including the number of personnel Pfizer claimed to have hired and planned to hire.
The documents also indicated the total number of Pfizer-BioNTech vaccine doses distributed worldwide from December 2020 to February 2021:
“It is estimated that approximately 126,212,580 doses of BNT162b2 [the Pfizer EUA vaccine] were shipped worldwide from the receipt of the first temporary authorisation for emergency supply on 01 December 2020 through 28 February 2021.”
The amount of dosages shipped had previously been redacted.
Pfizer omitted the negative reactions in the same materials.
“Based on Phase 1 data from the FIH Study BNT162-01, BNT162b1 and BNT162b2 [various vaccines tested during the trial period] were safe and well-tolerated in healthy adults 18 to 55 years of age, with no unanticipated safety findings,” the document states.
“Phase 2/3 safety data were generally concordant with safety data in Phase 1 of the study, both overall and with regard to younger and older participants.”
Pfizer gave specific information on the number of adverse occurrences seen later in the document.
“Through 28 February 2021 (data lock point aligned with Pharmacovigilance Plan), there were a total of 42,086 case reports (25,379 medically confirmed and 16,707 non-medically confirmed) containing 158,893 events. Cases were received from 63 countries.”
“Consistent with what was seen in Phase 2/3 of Study C4591001, most reported AEs were in System Organ Classes (SOCs) with reactogenicity events: general disorders and administration site conditions (51,335), nervous system disorders (25,957), musculoskeletal and connective tissue disorders (17,283), and gastrointestinal disorders (14,096).”
“Post-authorization data have also informed the addition of adverse drug reactions (ADRs) related to the experience of reactogenicity to the product labeling.”
Pfizer filed documentation to the FDA for complete approval of its Comirnaty COVID vaccine in May 2021, and the document release on April 1 included a “request for priority review” of the documentation.
In this document, Pfizer claims that its vaccine addresses a “unmet medical need,” asserting that “Mass immunization with a safe and effective vaccine against COVID-19 can dramatically alter the trajectory of the pandemic.”
Pfizer raised “concerns” about removing COVID safety precautions including lockdowns, claiming that doing so would “counteract the impacts of this vaccination effort.”
According to the document:
“Vaccination against COVID-19 began with EUA/conditional approvals in December 2020, in a phased rollout defined by national/regional guidance.
However, there continue to be concerning trends that may counteract the impacts of this vaccination effort, including:[L]imitations in access to obtaining a vaccine due to infrastructure challenges (ie, clinic and appointment capacity and systems)
[I]ncreasing viral transmission fueled by relaxed compliance with mitigations as the pandemic surpasses the 1-year mark (ie, masks, physical distancing, limiting travel)
[I]ncreasing circulation of emerging variants of concern (which are currently driving continued spread of viral infection in Europe despite extensive mitigation mandates).”
Pfizer justified its request for full licensure of its COVID vaccine on the following basis:
A vaccine program must be implemented expediently and rapidly expanded to have a significant impact on the pandemic course.
Licensure of BNT162b2 is likely to enhance vaccine uptake by facilitating supply of vaccine from Pfizer/BioNTech directly to pharmacies and healthcare providers/facilities.
The greatest impact of BNT162b2 licensure may be direct supply to healthcare providers who serve vulnerable populations such as elderly patients and those who live in rural and underserved communities (ie, individuals who might be unable to navigate the challenges of securing vaccine access using the systems in place for EUA).
Expansion of vaccine via licensure would ultimately improve the prospect of achieving population herd immunity to bring the pandemic under control.”
In a statement to The Defender, Brian Hooker, chief scientific officer of Children’s Health Defense, said:
“The rollout of the Pfizer vaccine has led to an unprecedented number of adverse events reported — 158,000 adverse events in the first two-plus months of the rollout means that the rate of reported AE [adverse events] was approximately 1:1000, with many of the AEs graded as serious. This is based on a denominator of 125,000,000 vaccines distributed.”
“It is no wonder that an army of 1,800 individuals was needed to process all of the information.”
“Hooker noted the total number (1,205,755) of COVID vaccine adverse events reported to the Vaccine Adverse Event Reporting System between Dec. 14, 2020 and March 25, 2022, now eclipses the total number (930,952) of adverse events reported in the 32-year history of the database.”
Pfizer committed fraud, and compounded the deceit by recruiting over a thousand full-time personnel “to deal with the flood of adverse events that they expected- and yet they told no one about this publicly,” according to Stevan Looney, a civil trial and appellate attorney in New Mexico.
On page 1 of the Pfizer report, it states:
“The information contained in this document is proprietary and confidential. Any disclosure, reproduction, distribution, or other dissemination of this information outside of Pfizer, its Affiliates, its Licensees, or Regulatory Agencies is strictly prohibited. Except as may be otherwise agreed to in writing, by accepting or reviewing these materials, you agree to hold such information in confidence and not to disclose it to others (except where required by applicable law), nor to use it for unauthorized purposes.”
The next batch of documents will be released on or before May 1st.
The secret document is given below:reissue_5.3.6-postmarketing-experience